![]() | Up a level |
Abdollahpour-Alitappeh, M and Lotfinia, M and Gharibi, T and Mardaneh, J and Farhadihosseinabadi, E and Larki, P and Faghfourian, B and Sepehr, K and Abbaszadeh-Goudarzi, K and Abbaszadeh-Goudarzi, G and Johari, B and Zali, M and Bagheri, N (2019) Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal of Cellular Physiology, 234 (5).
Abdollahpour-Alitappeh, M and Lotfinia, M and Gharibi, T and Mardaneh, J and Farhadihosseinabadi, B and Larki, P and Faghfourian, B and Sepehr, KS and Abbaszadeh-Goudarzi, K and Abbaszadeh-Goudarzi, G and Johari, B and Zali, MR and Bagheri, N (2018) Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol.
Abdollahpour-Alitappeh, M and Lotfinia, M and Bagheri, N and Sineh Sepehr, K and Habibi-Anbouhi, M and Kobarfard, F and Balalaie, S and Foroumadi, A and Abbaszadeh-Goudarzi, G and Abbaszadeh-Goudarzi, K and Abolhassani, M (2018) Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. J Cell Physiol.